[
    [
        {
            "time": "",
            "original_text": "华兰生物：变更公司证券事务代表",
            "features": {
                "keywords": [
                    "华兰生物",
                    "证券事务代表",
                    "变更"
                ],
                "sentiment_score": 0.2,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "华兰生物：变更公司证券事务代表",
                "Correlation": 9,
                "Sentiment": 5,
                "Importance": 4,
                "Impact": 3,
                "Duration": 2,
                "Entity_Density": 8,
                "Market_Scope": 2,
                "Time_Proximity": 6,
                "Headline_Structure": 5,
                "Source_Recency": 7
            }
        },
        {
            "time": "2020-H1",
            "original_text": "2020年H1疫苗批签发报告：二季度批签发环比、同比显着提升 国产13价肺炎疫苗等表现强劲",
            "features": {
                "keywords": [
                    "2020年H1",
                    "疫苗",
                    "批签发",
                    "环比提升",
                    "同比提升",
                    "国产13价肺炎疫苗"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "生物医药",
                    "疫苗"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "2020年H1疫苗批签发报告：二季度批签发环比、同比显着提升 国产13价肺炎疫苗等表现强劲",
                "Correlation": 8,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 6,
                "Market_Scope": 8,
                "Time_Proximity": 5,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        },
        {
            "time": "",
            "original_text": "医药生物行业：人血白蛋白与静丙批签发量大幅增长，进口白蛋白占比提升明显，维持“买入”评级",
            "features": {
                "keywords": [
                    "医药生物",
                    "人血白蛋白",
                    "静丙",
                    "批签发量增长",
                    "进口白蛋白",
                    "买入评级"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "医药生物行业：人血白蛋白与静丙批签发量大幅增长，进口白蛋白占比提升明显，维持“买入”评级",
                "Correlation": 7,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 5,
                "Market_Scope": 9,
                "Time_Proximity": 5,
                "Headline_Structure": 6,
                "Source_Recency": 6
            }
        },
        {
            "time": "",
            "original_text": "双林生物重组遭问询：派斯菲科的药品GMP证书曾被收回 问询",
            "features": {
                "keywords": [
                    "双林生物",
                    "重组",
                    "问询",
                    "派斯菲科",
                    "GMP证书",
                    "收回"
                ],
                "sentiment_score": -0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "双林生物重组遭问询：派斯菲科的药品GMP证书曾被收回 问询",
                "Correlation": 9,
                "Sentiment": 3,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 3,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        }
    ]
]